Bronx, NY

DaVita Clinical Research

Kidney Diseases

Obesity

Nephritis

Calciphylaxis

Lupus Nephritis

Membranous Glomerulonephritis

Membranoproliferative Glomerulonephritis

IGA Glomerulonephritis

Overweight

Glomerulonephritis

SNF472

APL-2

Tirzepatide

LY3298176

Apellis Pharmaceuticals

Lilly

Sanifit

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

DaVita Clinical Research | Bronx, NY

Site insights

Work at this site?

Active trials

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

Trial sponsors